This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in
treating patients with diffuse large B-cell lymphoma that has returned after a period of
improvement or does not respond to treatment. TGR-1202 and ibrutinib may stop the growth of
cancer cells by blocking some of the enzymes needed for cell growth.